Cargando…

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells

Purpose of our study was to explore a new immunotherapy for high grade soft tissue sarcomas (STS) based on cytokine-induced killer cells (CIK) redirected with a chimeric antigen receptor (CAR) against the tumor-promoting antigen CD44v6. We aimed at generating bipotential killers, combining the CAR s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leuci, V., Casucci, G. M., Grignani, G., Rotolo, R., Rossotti, U., Vigna, E., Gammaitoni, L., Mesiano, G., Fiorino, E., Donini, C., Pisacane, A., ambrosio, L. D., Pignochino, Y., Aglietta, M., Bondanza, A., Sangiolo, D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927525/ https://www.ncbi.nlm.nih.gov/pubmed/29721373 http://dx.doi.org/10.1080/2162402X.2017.1423167

Ejemplares similares

Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST
por: Fiorino, Erika, et al.
Publicado: (2022)

CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
por: Giraudo, Lidia, et al.
Publicado: (2023)

Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.
por: Mesiano, Giulia, et al.
Publicado: (2018)

Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukocyte antigen barriers
por: Circosta, Paola, et al.
Publicado: (2022)

CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy
por: Rotolo, Ramona, et al.
Publicado: (2019)

Activity of cytokine-induced killer cells against bone and soft tissue sarcoma
por: Sangiolo, Dario, et al.
Publicado: (2014)

EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing’s Sarcoma and Chondrosarcoma
por: Giordano, Giorgia, et al.
Publicado: (2021)

Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells
por: Gammaitoni, Loretta, et al.
Publicado: (2015)

Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity
por: Leuci, V., et al.
Publicado: (2016)

Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective
por: Donini, Chiara, et al.
Publicado: (2021)

Suicide Gene Therapy to Increase the Safety of Chimeric Antigen Receptor-Redirected T Lymphocytes
por: Casucci, Monica, et al.
Publicado: (2011)

PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study
por: Pignochino, Ymera, et al.
Publicado: (2021)

Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy
por: Chiriaco, Cristina, et al.
Publicado: (2022)

Recruitment, Infiltration, and Cytotoxicity of HLA-Independent Killer Lymphocytes in Three-Dimensional Melanoma Models
por: Iaia, Ilenia, et al.
Publicado: (2021)

Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer
por: Capellero, S., et al.
Publicado: (2020)

Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1(+) Chemoresistant Lung Cancer Cells
por: Rotolo, Ramona, et al.
Publicado: (2023)

The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma
por: Pignochino, Ymera, et al.
Publicado: (2015)

CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice
por: Porcellini, Simona, et al.
Publicado: (2020)

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours
por: Martin, Valentina, et al.
Publicado: (2019)

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
por: Pignochino, Ymera, et al.
Publicado: (2017)

DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination
por: Merlini, Alessandra, et al.
Publicado: (2022)

CIK Cells and HDAC Inhibitors in Multiple Myeloma
por: Stephan, David, et al.
Publicado: (2017)

Enhancing T cell persistence of CAR-redirected T cells in solid tumors
por: Guedan, Sonia, et al.
Publicado: (2014)

Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform
por: Borrok, M. Jack, et al.
Publicado: (2022)

Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR
por: Zhang, Angela Q., et al.
Publicado: (2023)

Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden
por: Biondi, Marta, et al.
Publicado: (2023)

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes
por: Caruana, Ignazio, et al.
Publicado: (2015)

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
por: Pignochino, Ymera, et al.
Publicado: (2009)

Identification of Targets to Redirect CAR T Cells in Glioblastoma and Colorectal Cancer: An Arduous Venture
por: Ponterio, Eleonora, et al.
Publicado: (2020)

Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies
por: Abbott, Rebecca C., et al.
Publicado: (2020)

Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
por: Huckaby, Justin T, et al.
Publicado: (2021)

Next-Generation Manufacturing Protocols Enriching T(SCM) CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients
por: Arcangeli, Silvia, et al.
Publicado: (2020)

P1361: SLEEPING BEAUTY PLATFORM FOR ENGINEERING CAR-CIK CELLS TOWARD A MULTI-TARGETING STRATEGY IN B-ALL
por: Moretti, Alex, et al.
Publicado: (2023)

Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene
por: Casucci, Monica, et al.
Publicado: (2018)

Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights
por: Chiabotto, Giulia, et al.
Publicado: (2020)

Anti-CD19 CAR T cells potently redirected to kill solid tumor cells
por: Ambrose, Christine, et al.
Publicado: (2021)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective
por: Sharma, Amit, et al.
Publicado: (2021)

Cytokine-Induced Killer (CIK) Cells, In Vitro Expanded under Good Manufacturing Process (GMP) Conditions, Remain Stable over Time after Cryopreservation
por: Mareschi, Katia, et al.
Publicado: (2020)

Innovative Clinical Perspectives for CIK Cells in Cancer Patients
por: Introna, Martino, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fv7l8p7erknrav7u5qd9n2j5qq